BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yin L, Zhao C, Han J, Li Z, Zhen Y, Xiao R, Xu Z, Sun Y. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo. Ther Clin Risk Manag 2017;13:117-30. [PMID: 28223815 DOI: 10.2147/TCRM.S128575] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Makaremi S, Asadzadeh Z, Hemmat N, Baghbanzadeh A, Sgambato A, Ghorbaninezhad F, Safarpour H, Argentiero A, Brunetti O, Bernardini R, Silvestris N, Baradaran B. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. Biomedicines 2021;9:1075. [PMID: 34572263 DOI: 10.3390/biomedicines9091075] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
2 Kana SI, Essani K. Immuno-Oncolytic Viruses: Emerging Options in the Treatment of Colorectal Cancer. Mol Diagn Ther 2021;25:301-13. [PMID: 33713031 DOI: 10.1007/s40291-021-00517-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
3 Ren B, Liu X, Wang Y, Lyu Y, Xin H, Peng X, Xiang Y, Wang X, Xin H. Novel Functional Motifs of the Cell Entry Glycoprotein D for Oncolytic Herpes Simplex Viruses. YM 2021;05:266-286. [DOI: 10.4236/ym.2021.54025] [Reference Citation Analysis]
4 Syed Najmuddin SUF, Amin ZM, Tan SW, Yeap SK, Kalyanasundram J, Veerakumarasivam A, Chan SC, Chia SL, Yusoff K, Alitheen NB. Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice. PeerJ 2020;8:e9761. [PMID: 33354412 DOI: 10.7717/peerj.9761] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Deng L, Yang X, Fan J, Ding Y, Peng Y, Xu D, Huang B, Hu Z. IL-24-Armed Oncolytic Vaccinia Virus Exerts Potent Antitumor Effects via Multiple Pathways in Colorectal Cancer. Oncol Res 2021;28:579-90. [PMID: 32641200 DOI: 10.3727/096504020X15942028641011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
6 Hromic-Jahjefendic A, Lundstrom K. Viral Vector-Based Melanoma Gene Therapy. Biomedicines 2020;8:E60. [PMID: 32187995 DOI: 10.3390/biomedicines8030060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
7 Ding AS, Routkevitch D, Jackson C, Lim M. Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors. Front Immunol 2019;10:1715. [PMID: 31396227 DOI: 10.3389/fimmu.2019.01715] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
8 Zhang W, Wang F, Hu X, Liang J, Liu B, Guan Q, Liu S. Inhibition of colorectal cancer liver metastasis in BALB/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity. Oncol Lett 2019;17:815-22. [PMID: 30655834 DOI: 10.3892/ol.2018.9720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
9 Lundstrom K. New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy. Biologics. 2018;12:43-60. [PMID: 29445265 DOI: 10.2147/btt.s140114] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
10 Sanchala DS, Bhatt LK, Prabhavalkar KS. Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells. Front Pharmacol 2017;8:270. [PMID: 28559846 DOI: 10.3389/fphar.2017.00270] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]